T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
Sanmina
SANM
$11.1B
| $780K | ﹤0.01% |
32,252
+9,700
| +43% | +$223K |
|
1802
EPR Properties
EPR
$4.73B
| $779K | ﹤0.01% |
12,980
| – | – |
|
|
CVG
1803
DELISTED
Convergys
CVG
| $778K | ﹤0.01% |
34,000
-9,900
| -23% | -$209K |
|
|
PPO
1804
DELISTED
POLYPORE INTERNATIONAL, INC
PPO
| $777K | ﹤0.01% |
13,200
| – | – |
|
1805
Asbury Automotive
ABG
$3.78B
| $776K | ﹤0.01% |
9,340
+1,400
| +18% | +$108K |
|
1806
iShares Russell 2000 ETF
IWM
$82.4B
| $776K | ﹤0.01% |
6,239
| – | – |
|
|
CSG
1807
DELISTED
CHAMBERS STR PPTYS COM
CSG
| $773K | ﹤0.01% |
98,100
+31,900
| +48% | +$262K |
|
1808
Hancock Whitney
HWC
$6.37B
| $772K | ﹤0.01% |
25,860
| – | – |
|
1809
MillerKnoll
MLKN
$1.62B
| $770K | ﹤0.01% |
27,750
+3,600
| +15% | +$105K |
|
|
SMLR
1810
DELISTED
Semler Scientific
SMLR
| $766K | ﹤0.01% |
218,977
+5,900
| +3% | +$23.5K |
|
1811
Crane NXT
CXT
$2.96B
| $758K | ﹤0.01% |
34,954
| – | – |
|
|
STNR
1812
DELISTED
STEINER LEISURE LTD
STNR
| $754K | ﹤0.01% |
15,900
-6,300
| -28% | -$289K |
|
|
SHLM
1813
DELISTED
Schulman (A.) Inc
SHLM
| $753K | ﹤0.01% |
15,613
| – | – |
|
|
RYL
1814
DELISTED
RYLAND GROUP INC
RYL
| $753K | ﹤0.01% |
15,446
| – | – |
|
1815
Dillards
DDS
$9.59B
| $751K | ﹤0.01% |
5,500
| – | – |
|
|
IPXL
1816
DELISTED
Impax Laboratories, Inc.
IPXL
| $750K | ﹤0.01% |
16,000
-2,300
| -13% | -$91.5K |
|
|
VSTO
1817
DELISTED
Vista Outdoor Inc.
VSTO
| $747K | ﹤0.01% |
+17,450
| New | +$741K |
|
|
FSL
1818
DELISTED
FREESCALE SEMICONDUCTOR LTD
FSL
| $742K | ﹤0.01% |
18,200
-12,300
| -40% | -$424K |
|
1819
Dana Inc
DAN
$3.26B
| $741K | ﹤0.01% |
35,000
-4,860
| -12% | -$105K |
|
1820
WPP
WPP
$5.82B
| $740K | ﹤0.01% |
6,500
| – | – |
|
1821
Dolby
DLB
$5.84B
| $739K | ﹤0.01% |
19,362
-2,120
| -10% | -$84.6K |
|
|
MPT
1822
Medical Properties Trust
MPT
$2.51B
| $738K | ﹤0.01% |
50,100
+5,100
| +11% | +$75.8K |
|
|
TEF
1823
DELISTED
Telefonica
TEF
| $738K | ﹤0.01% |
68,158
+3,577
| +6% | +$39.3K |
|
|
UTX.PRA
1824
DELISTED
UNITED TECHNOLOGIES CORP CORP UNIT (DE)
UTX.PRA
| $734K | ﹤0.01% |
11,900
-100
| -0.8% | -$6.23K |
|
|
SKX
1825
DELISTED
Skechers
SKX
| $733K | ﹤0.01% |
30,600
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.